Shenzhen Salubris Pharmaceuticals (002294.SZ) issued an announcement according to the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security's release of "关于印发<国家基本医疗保险、工伤保险和生育保险药品目录(2024年)>的通知".
According to the announcement from Shenzhen Salubris Pharmaceuticals (002294.SZ) on the Zhitong Finance and Economics app, following the release of the《Notification on Printing and Distributing the National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2024)》(医保发〔2024〕33号), the company's innovative drugs Fulitantan (generic name: Alisartan Ester-Amlodipine Tablets) and Xinting (generic name: Benzoic Acid Voglibose Tablets) have been newly included in the Category B range of the《National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2024)》through negotiations.
The inclusion of these products in the national medical insurance catalog fully reflects the country's support and recognition of innovative drugs with high clinical value and reasonable prices. With the promotion of negotiated drugs entering hospitals and the improvement of the 'dual-channel' management mechanism, it will be more conducive to market promotion and sales, contributing to the company's future revenue and profits.
